Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Methotrexate in systemic lupus erythematosus.

J M Wong1, J M Esdaile

  • 1Arthritis Research Centre of Canada, Vancouver, Canada.

Lupus
|March 9, 2005
PubMed
Summary

Methotrexate (MTX) use for moderate systemic lupus erythematosus (SLE) shows mixed results. While some studies suggest benefits for skin and joint symptoms, randomized trials offer conflicting evidence on overall disease activity.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Arboviral vaccines for use in pregnant travelers.

Travel medicine and infectious disease·2023
Same author

Fluctuating selection and global change: a synthesis and review on disentangling the roles of climate amplitude, predictability and novelty.

Proceedings. Biological sciences·2021
Same author

Bioequivalence and pharmacokinetic comparison of two fixed dose combination of Metformin/ Glibenclamide formulations in healthy subjects under fed condition.

The Medical journal of Malaysia·2020
Same author

Relationship between physical activity and hip pain in persons with and without cam or pincer morphology: a population-based case-control study.

Osteoarthritis and cartilage·2017
Same author

Hes1 Increases the Invasion Ability of Colorectal Cancer Cells via the STAT3-MMP14 Pathway.

PloS one·2015
Same author

The validity of a non-radiologist reader in identifying cam and pincer femoroacetabular impingement (FAI) using plain radiography.

Rheumatology international·2015

Area of Science:

  • Rheumatology
  • Immunology
  • Clinical Pharmacology

Background:

  • Optimal treatment for moderate, non-organ-threatening systemic lupus erythematosus (SLE) is not well-established.
  • Methotrexate (MTX) is frequently employed for SLE management, particularly for cutaneous and articular manifestations.
  • Existing evidence includes uncontrolled case series and a retrospective cohort, with limited prospective data.

Purpose of the Study:

  • To evaluate the efficacy of methotrexate (MTX) in treating moderate systemic lupus erythematosus (SLE).
  • To analyze the existing evidence regarding MTX's impact on disease activity and corticosteroid requirements in SLE patients.
  • To discuss challenges inherent in conducting clinical trials for moderately active SLE.

Main Methods:

  • Review and synthesis of data from 20 uncontrolled case series.
  • Analysis of findings from a single retrospective cohort study.
  • Examination of results from three prospective randomized controlled trials (RCTs).

Main Results:

  • Uncontrolled studies and retrospective data suggest MTX may benefit active skin and joint disease in SLE.
  • Two RCTs indicated overall disease activity improvement and reduced corticosteroid needs with MTX.
  • One RCT found no significant benefit for overall disease activity but noted a reduction in corticosteroid use.

Conclusions:

  • The efficacy of methotrexate (MTX) for moderate systemic lupus erythematosus (SLE) remains inconclusive due to conflicting trial results.
  • MTX may offer a corticosteroid-sparing effect in SLE patients, even if overall disease activity is not significantly impacted.
  • Conducting rigorous clinical trials in moderately active SLE presents unique methodological challenges.

Related Experiment Videos